Сравнение

Maridebart Cafraglutide vs. Pemvidutide

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Метаболизм

Номер CAS

нет данных

Молекулярная масса

нет данных

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Maridebart Cafraglutide

MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.

Pemvidutide

The GLP-1 component suppresses appetite while the glucagon component raises energy expenditure and acts directly on hepatic fat metabolism — the combination is intended to mimic the complementary effects of diet and exercise.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследование на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Maridebart Cafraglutide	Pemvidutide
Германия	Не одобрено	Не одобрено
США	Не одобрено	Не одобрено

Полные записи

Maridebart Cafraglutide

Полная запись →

Pemvidutide

Полная запись →

Frequently asked questions

What is the difference between Maridebart Cafraglutide and Pemvidutide?: Maridebart Cafraglutide is classified as "Метаболизм", while Pemvidutide is classified as "Метаболизм". Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. Pemvidutide: Pemvidutide is a 29-amino-acid GLP-1/glucagon dual receptor agonist (Altimmune) under investigation for obesity and the fatty-liver disease MASH. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Maridebart Cafraglutide or Pemvidutide?: The highest available evidence level is "РКИ на людях" for Maridebart Cafraglutide and "Исследование на людях" for Pemvidutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Maridebart Cafraglutide and Pemvidutide in Germany and the United States?: Германия: Maridebart Cafraglutide — Не одобрено, Pemvidutide — Не одобрено. США: Maridebart Cafraglutide — Не одобрено, Pemvidutide — Не одобрено. These are factual summaries with source and review date on the individual pages.

Country

Maridebart Cafraglutide

Pemvidutide

Германия

Не одобрено

США

Не одобрено

Frequently asked questions

What is the difference between Maridebart Cafraglutide and Pemvidutide?

Maridebart Cafraglutide is classified as "Метаболизм", while Pemvidutide is classified as "Метаболизм". Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. Pemvidutide: Pemvidutide is a 29-amino-acid GLP-1/glucagon dual receptor agonist (Altimmune) under investigation for obesity and the fatty-liver disease MASH. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Maridebart Cafraglutide or Pemvidutide?

The highest available evidence level is "РКИ на людях" for Maridebart Cafraglutide and "Исследование на людях" for Pemvidutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Maridebart Cafraglutide and Pemvidutide in Germany and the United States?

Германия: Maridebart Cafraglutide — Не одобрено, Pemvidutide — Не одобрено. США: Maridebart Cafraglutide — Не одобрено, Pemvidutide — Не одобрено. These are factual summaries with source and review date on the individual pages.